Compare Moderna, Inc. (MRNA) vs Pfizer Inc (PFE) Price & Performance

Moderna, Inc.Trade

Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Pfizer Inc — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Pfizer Inc trades at $24.92 (market cap $141.06B). The key difference: Pfizer Inc is far larger — about 6× Moderna, Inc.'s market cap, and Pfizer Inc pays a 6.95% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

	MRNA	PFE
Market Cap	$23.60B	$141.06B
Sector	Health	Health
52-Week High	$81.80	$28.56
52-Week Low	$22.36	$23.29
Enterprise Value	$19.70B	$191.72B
Volume	—	29,869,932
Dividend Yield	—	6.95%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

No Aura AI signal available yet.

Pfizer Inc

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.

The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRNA

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 12 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

PFE

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.